# Safety, Tolerability, and Pharmacokinetics of SAB-176 in Healthy Participants

> **NCT04471038** · PHASE1 · COMPLETED · sponsor: **SAb Biotherapeutics, Inc.** · enrollment: 27 (actual)

## Conditions studied

- Influenza Type A
- Influenza Type B
- Influenza

## Interventions

- **BIOLOGICAL:** SAB-176
- **OTHER:** Normal Saline

## Key facts

- **NCT ID:** NCT04471038
- **Lead sponsor:** SAb Biotherapeutics, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2020-07-29
- **Primary completion:** 2021-04-19
- **Final completion:** 2021-04-19
- **Target enrollment:** 27 (ACTUAL)
- **Last updated:** 2025-01-06


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04471038

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04471038, "Safety, Tolerability, and Pharmacokinetics of SAB-176 in Healthy Participants". Retrieved via AI Analytics 2026-08-17 from https://api.ai-analytics.org/clinical/NCT04471038. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*